Kurzfassung

A randomized, multicenter, double-blind, phase III trial comparing the efficacy of
Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in subjects with newly diagnosed extensive-stage disease Small Cell Lung Cancer (ED-SCLC)